Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New group therapy shows promise for easing anxiety and depression

NCT ID NCT06863948

Symptom relief Sponsor: S.LAB (SOLOWAYS) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new type of group therapy called Terebenin's Method for adults with mild to moderate anxiety and depression. The therapy combines role-playing, body awareness, and guided discussion in weekly sessions over 8 weeks. Researchers measured changes in symptoms and stress-related biomarkers like cortisol. The goal was to see if this approach could help reduce anxiety and depression and to gather data for a larger future study.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Terebenin's Method (integrative group psychotherapy combining psychodrama, systemic constellation, body-oriented practices, and directive therapy)
What this could lead to
If it works, this could offer a new group therapy option for people with mild to moderate anxiety and depression, potentially reducing symptoms and stress.
What could go wrong
This is a small pilot study with only 66 participants, so results may not apply to everyone. It's early-stage research, and the therapy may not prove more effective than standard treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

66 people

The number who actually took part.

Started

May 2024

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18-60. * Subclinical, mild, or moderate anxiety/depressive symptoms (screened via HADS, BDI-II, STAI). * No current psychotropic medication use or on a stable dose for ≥4 weeks with no planned changes. * Ability to attend weekly group sessions for 8 weeks + follow-up visits, including saliva sample collection. * Provision of written informed consent. Exclusion Criteria: * Severe psychiatric disorders (e.g., schizophrenia, bipolar disorder in a manic phase, major depression with psychotic features). * Significant suicidal risk requiring urgent intervention. * Severe somatic illness impeding participation. * Active substance use disorder unless in stable remission for \>6 months. * Ongoing psychotherapy that could confound results. * Inability to comply with saliva collection (e.g., shift work, severe sleep disturbances).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anxiety are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anxiety anxiety disorder depressive disorder major depressive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anxiety Depression - major depressive disorder

Contacts and locations

Locations

  • Center for New Medical Technologies

    Novosibirsk, 630090, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.